The central role of dendritic cells (DC) in the immune system and their unique potency to induce tumor-specific killer and helper T cells has been demonstrated in numerous studies and is today unequivocal. Therefore, DCbased immunotherapy represents one of the most promising approaches to fight cancer and since the first vaccination study in 1996 numerous trials have been performed with more than 30 DC-based vaccination trials published only in the past 3 years. In principle, antigen can be delivered to DC by various strategies, but most commonly HLA class I or II restricted peptides derived from defined tumor antigens have been used. Because peptides can be readily obtained in clinical grade quality, are easily standardized and facilitate the immuno-monitoring during clinical trials, they can still be considered as gold standard of DC antigen loading.
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Nevertheless, several issues concerning the use of peptideloaded DC still have to be addressed. In the present study we carefully analyzed different parameters such as peptide concentration, stability of HLA/peptide complexes on immature (i-DC) versus mature-DC (m-DC) or antigen competition in order to optimize the loading of DC with HLA class I and II peptides. This article is available from: http://www.cancerci.com/content/4/S1/S43
